Acute myeloid leukemia, biallelic CEBPA gene mutation
MONDO:0100413Any acute myeloid leukemia that has the chromosomal anomaly biallelic CEBPA gene mutation. (The presence of mutations in both alleles of the CEBPA gene.)
Also known as: AML, C/EBP-Alpha Biallelic Gene Mutation, AML, C/EBPalpha Biallelic Gene Mutation, AML, CCAAT Enhancer Binding Protein Alpha Biallelic Gene Mutation, AML, CCAAT/Enhancer Binding Protein Alpha Biallelic Gene Mutation, AML, CCAAT/Enhancer Binding Protein, Alpha Biallelic Gene Mutation, AML, CEBP Biallelic Gene Mutation, AML, CEBPA Biallelic Gene Mutation, AML, CEBPA Biallelic Mutation
2961 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
Showing the 400 most recently updated of 573 trials in this tab.
-
Can specially trained immune cells flush out hidden HIV?
⭐️ CURE ⭐️ OngoingThis early-stage trial is testing whether immune cells from a donor, specially trained to attack HIV, can safely reduce the hidden HIV reservoir in people who have had a bone marrow transplant. Participants are adults with HIV who are on antiretroviral therapy and have already re…
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Can the HPV vaccine protect stem cell transplant patients?
⭐️ VACCINE ⭐️ OngoingThis study tests whether the Gardasil 9 vaccine can help stem cell transplant patients build immunity against HPV. About 48 adults who had a stem cell transplant for blood cancer will receive the vaccine. Researchers will measure antibody levels to see if the vaccine works in the…
Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 18, 2026 00:00 UTC
-
New vaccine aims to better protect blood cancer patients from COVID-19
⭐️ VACCINE ⭐️ OngoingThis study tests a new COVID-19 vaccine (GEO-CM04S1) in 63 adults with blood cancers like leukemia or lymphoma who have had a stem cell transplant or cell therapy. The goal is to see if this vaccine triggers a stronger immune response than standard mRNA vaccines, potentially offe…
Phase: PHASE2 • Sponsor: GeoVax, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:04 UTC
-
Cancer drug targets genetic weakness in advanced tumors
Disease control OngoingThis phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Special blood storage could cut transfusions for cancer patients
Disease control OngoingThis study tests whether red blood cells stored with less oxygen (hypoxic RBCs) are safer and more effective than standard transfusions for people with blood cancers who need regular blood. About 24 adults with transfusion-dependent blood cancers will receive both types of blood …
Phase: NA • Sponsor: Hemanext • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New cancer drug CHS-114 enters first human tests
Disease control OngoingThis early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…
Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Cancer drug pertuzumab tested for Long-Term use in extension trial
Disease control OngoingThis study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: drug targets DNA repair weakness
Disease control OngoingThis phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Precision drug shows promise for rare Gene-Driven cancers
Disease control OngoingThis study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…
Phase: PHASE1, PHASE2 • Sponsor: ImCheck Therapeutics, an Ipsen company • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental cancer combo targets Hard-to-Treat tumours
Disease control OngoingThis early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Re…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill shrink advanced tumors? a new drug steps into the spotlight
Disease control OngoingThis early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Cancer patients who respond to drug get continued access in new study
Disease control ENROLLING_BY_INVITATIONThis study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New cancer drug SG2918 enters first human tests
Disease control OngoingThis early-stage trial tests an experimental drug called SG2918 in 17 people with advanced cancers that no longer respond to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive the drug by IV every three w…
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug SG301 tested in blood cancer patients who have run out of options
Disease control OngoingThis early-stage trial is testing a new drug called SG301 in about 61 people with blood cancers like multiple myeloma that have returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose to use in future studies. Researche…
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a smart drug home in on Hard-to-Treat cancers?
Disease control OngoingThis trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control OngoingThis early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…
Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New cancer drug combo targets Hard-to-Treat tumors
Disease control TerminatedThis early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Cancer drug olaparib gets a makeover: which pill works best?
Disease control OngoingThis phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Personalized cancer attack: new trial matches drugs to tumor genes
Disease control OngoingThis phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug ONO-7428 enters first human tests for advanced cancers
Disease control OngoingThis early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be m…
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could dropping one drug make stem cell transplants safer?
Disease control OngoingThis study looks at whether it is safe to remove one immune-suppressing drug, mycophenolate mofetil (MMF), from the standard treatment plan after a stem cell transplant for blood cancers. Sixty adults aged 18 to 75 will receive the transplant without MMF and be monitored for up t…
Phase: PHASE2 • Sponsor: Ronald Paquette • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
Disease control OngoingThis early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…
Phase: PHASE1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New antibody combo tested against hard-to-treat cancers
Disease control OngoingThis early-phase trial tests an experimental antibody called GEN1042, given alone or with the cancer drug pembrolizumab (and sometimes chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check …
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody combo shows promise in early cancer trial
Disease control OngoingThis trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New Immune-Boosting drug GEN1042 tested in japanese cancer patients
Disease control OngoingThis early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental PARP inhibitor enters human trials
Disease control OngoingThis study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…
Phase: PHASE1, PHASE2 • Sponsor: Acerand Therapeutics (Shanghai) Limited • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Cancer drug brigimadlin tested for Long-Term use in solid tumour patients
Disease control OngoingThis study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Cancer drug regorafenib gets a second chance in small continuation study
Disease control OngoingThis study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Experimental drug combo shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests a new drug called TRC102 (methoxyamine) combined with standard chemotherapy (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. The goal is to see if TRC102 can make cancer cells more sensitiv…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug combo shows promise for tough cancers
Disease control OngoingThis early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New cancer drug saruparib enters early human testing
Disease control OngoingThis early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
DNA-Guided prescribing may shield young cancer patients from harmful drug reactions
Disease control OngoingThis trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …
Phase: NA • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Could a common sedative boost survival after cancer surgery in seniors?
Disease control OngoingThis study looked at whether adding dexmedetomidine to standard morphine pain relief after cancer surgery helps elderly patients (65-90 years) live longer. 1,500 participants were randomly assigned to receive either morphine alone or morphine plus dexmedetomidine for three days a…
Phase: NA • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Cancer drug RVU120 gets extended trial for ongoing patients
Disease control ENROLLING_BY_INVITATIONThis study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Cancer drug futibatinib gets a safety check in Long-Term rollover study
Disease control OngoingThis study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…
Phase: PHASE2, PHASE3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New cancer drug IPH4502 enters first human tests
Disease control OngoingThis early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …
Phase: PHASE1 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Cancer patients get extended access to promising immunotherapy
Disease control OngoingThis study offers continued treatment with atezolizumab (Tecentriq) to about 1,000 cancer patients who were already benefiting from it in earlier Roche-sponsored trials. Participants may also receive other drugs like bevacizumab or alectinib. The main goal is to provide ongoing a…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a pill that starves tumors of oxygen help fight advanced cancer?
Disease control OngoingThis early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…
Phase: PHASE1 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
Disease control OngoingThis phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug INCB123667 enters human trials for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial is testing a new drug called INCB123667, taken as a tablet, in people with advanced solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with other cancer therapies. The main goals are to…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Gene-Silencing drug shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug that targets a specific gene (EphA2) to slow tumor growth in people with advanced solid tumors that have spread or returned. About 49 participants will receive the drug to find the safest dose and check for side effects. The goal is to cont…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Personalized weight loss coaching could help cancer survivors shed pounds
Disease control OngoingThis study tests different levels of a telephone-based weight loss program for cancer survivors who are overweight or obese. All participants start with a core program including written materials, a smartphone app, and optional coaching. Those who lose at least 2% of their weight…
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Targeted drug takes aim at NF1-Mutated cancers
Disease control OngoingThis phase II trial is testing the drug trametinib in 50 people with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from get…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental drug SHR-A2009 takes first steps against Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug cocktail targets advanced cancers in early trial
Disease control OngoingThis Phase I trial tests the safety and best dose of combining vorinostat with one of three mTOR inhibitors (sirolimus, everolimus, or temsirolimus) in up to 249 patients with advanced cancer that has not responded to standard treatments. The drugs aim to block cancer cell growth…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug SG1827 enters first human tests for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could goat milk help prevent a deadly transplant side effect?
Disease control OngoingThis early-phase study tests whether drinking milk from genetically engineered goats (which produce a human enzyme found in breast milk) can reduce the risk of graft versus host disease—a serious immune reaction—in blood cancer patients receiving a donor stem cell transplant. Abo…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New pill plus immunotherapy shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …
Phase: PHASE1, PHASE2 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in japanese patients
Disease control OngoingThis study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…
Phase: PHASE1, PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Cancer patients get continued access to atezolizumab in Long-Term study
Disease control OngoingThis study offers continued treatment with atezolizumab (Tecentriq) for cancer patients who were already receiving it in a prior Roche-sponsored trial. It includes 382 participants and aims to provide uninterrupted therapy while monitoring long-term safety and survival. The study…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Oral chemotherapy candidate utidelone moves to human testing for advanced cancers
Disease control OngoingThis early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …
Phase: PHASE1 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New immunotherapy targets tough pancreatic cancers in early trial
Disease control OngoingThis early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…
Phase: PHASE1, PHASE2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Targeted drug palbociclib tested against cancers with specific genetic flaw
Disease control OngoingThis phase II trial is testing the drug palbociclib in 40 patients whose advanced cancers have extra copies of the CCND1, 2, or 3 genes. Palbociclib blocks proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. The study …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug (veliparib) combined with two chemotherapy drugs (cyclophosphamide and doxorubicin) in people with advanced solid tumors or non-Hodgkin lymphoma that cannot be removed by surgery or have spread. The main goal is to find the safest dose and …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental drug COH29 targets tumor growth enzyme in advanced cancers
Disease control OngoingThis early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Pushing a weighted sled may help cancer patients build muscle and lose fat
Disease control OngoingThis pilot study tests whether a resistance training program using weighted sled pushes and pulls can help cancer patients improve muscle mass and reduce body fat. Thirty adults aged 20-89 with a cancer diagnosis will participate in monitored exercise sessions over six months. Re…
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New immunotherapy combo tested in kids with Hard-to-Treat cancers
Disease control OngoingThis study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New antibody combo aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 peo…
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called WJ47156, alone or combined with other anti-cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of tumor shrink…
Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Supercharged immune cells take aim at childhood cancers
Disease control OngoingThis study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Cancer drug safety tracked over years in ongoing study
Disease control OngoingThis study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control TerminatedThis study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…
Phase: PHASE1, PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingThis study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…
Phase: PHASE2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to outsmart resistant cancers
Disease control OngoingThis early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…
Phase: PHASE1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug shows promise for rare joint tumor in early trial
Disease control OngoingThis study tests a drug called vimseltinib in people with a rare joint tumor (tenosynovial giant cell tumor, or TGCT) and advanced solid tumors. The drug blocks a protein that helps these tumors grow. The trial has two phases: first, finding the safest dose, then expanding to see…
Phase: PHASE1, PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New antibody drug takes on advanced tumors in first human trial
Disease control OngoingThis early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…
Phase: PHASE1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests whether adding the targeted drug copanlisib to two immunotherapy drugs (nivolumab and ipilimumab) can better control advanced solid tumors that have changes in the PIK3CA or PTEN genes. About 54 adults with cancers that have spread or cannot be removed will recei…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …
Phase: PHASE1 • Sponsor: BioNTech Cell & Gene Therapies GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to boost immune attack on hard-to-treat cancers
Disease control OngoingThis early-phase study tests the safety of the immunotherapy drug atezolizumab given after a patient's own immune cells have been modified and infused back (adoptive cell transfer). It includes 40 adults with advanced blood or solid cancers that no longer respond to standard trea…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered virus targets Hard-to-Treat cancers in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…
Phase: PHASE1, PHASE2 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted therapy hopes to shrink Hard-to-Treat ovarian cancers
Disease control OngoingThis study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with resistant tumors: drug combo enters safety trial
Disease control OngoingThis early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cell therapy aims to fight advanced cancers
Disease control TerminatedThis study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cancer drug injected into tumors shows promise in early trial
Disease control TerminatedThis early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New program helps cancer survivors fight heart disease with exercise
Disease control OngoingThis study tests a clinic program called ActivityChoice that helps cancer survivors become more physically active to lower their risk of heart disease. About 114 adult cancer survivors will be offered a choice of group in-person, group virtual, or self-monitored digital exercise …
Phase: NA • Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug targets Hard-to-Treat cancers with PTEN loss
Disease control OngoingThis phase II trial tests a drug called GSK2636771 in 35 patients whose cancers have lost a protein called PTEN. The drug blocks a growth signal that these cancers may rely on. Researchers hope to see if it can shrink tumors or stop them from growing.
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy aims to boost Radiation's punch with fewer side effects
Disease control TerminatedThis early-phase study tests a new way to treat advanced solid tumors by combining low-dose radiation with a drug called 5-aminolevulinic acid (ALA). The drug is thought to make cancer cells more sensitive to radiation, allowing lower doses to be used and potentially reducing har…
Phase: PHASE1 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo shows promise against tough cancers
Disease control OngoingThis early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…
Phase: PHASE1 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo targets cancer in brain and spine
Disease control OngoingThis early-phase study tests whether adding the drug azeliragon to radiation therapy is safe for people whose cancer has spread to the lining of the brain and spinal cord. About 21 adults with solid tumors or aggressive brain cancers will receive the combination. The main goal is…
Phase: PHASE1 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Virus therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…
Phase: PHASE1 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to outsmart stubborn cancers
Disease control OngoingThis early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Drug combo shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …
Phase: PHASE1 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for Hard-to-Treat cancers: DB-1305 enters human trials
Disease control OngoingThis study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New pill targets rare gene mutations in advanced cancers
Disease control OngoingThis study tests an experimental drug called KL590586, taken as a capsule, in people with advanced solid tumors that have specific RET gene changes. The trial has two phases: Phase I checks safety and the right dose, while Phase II looks at how well the drug shrinks tumors. Up to…
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for NRAS-Mutant cancers: targeted drug binimetinib under study
Disease control OngoingThis phase II trial is testing the drug binimetinib in 53 people whose cancers (excluding melanoma) have a specific genetic change called an NRAS mutation. Binimetinib blocks certain proteins that help these cancer cells grow. The study aims to see if the drug can shrink tumors o…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Targeted drug crizotinib tested against rare ALK-driven cancers
Disease control OngoingThis phase 2 trial tests the drug crizotinib in patients with advanced cancers (other than lung cancer) that have a specific genetic change called ALK rearrangement. Crizotinib works by blocking the ALK protein, which may stop cancer cells from growing. The study enrolled only 5 …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Targeted drug trametinib tested on rare BRAF cancers
Disease control OngoingThis phase II trial tests the drug trametinib in 35 patients with advanced cancers that have certain BRAF mutations or fusions. The goal is to see if trametinib can shrink or stop cancer growth by blocking proteins that help cancer cells grow. The study focuses on patients whose …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Targeted drug shows promise for rare HER2-Positive cancers
Disease control OngoingThis study tests a drug called ado-trastuzumab emtansine in people whose cancers have too many HER2 receptors (HER2 amplification), but not breast or stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Researchers want …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug ZW191 targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…
Phase: PHASE1 • Sponsor: Zymeworks BC Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Targeted drug shows promise for rare NF2-Mutated cancers
Disease control OngoingThis phase II trial is testing the drug defactinib in 35 patients whose advanced cancers have a specific genetic change called an NF2 mutation. The drug works by blocking a protein that may help these cancer cells grow. Researchers want to see if defactinib can shrink tumors or s…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug targets AKT mutation in Hard-to-Treat cancers
Disease control OngoingThis phase 2 trial tests capivasertib (AZD5363) in 35 patients with advanced cancers that have an AKT mutation. The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing.
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called copanlisib in people whose cancers have a specific genetic mutation (PIK3CA). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with advanced…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis phase II trial tests the drug taselisib in 70 patients with advanced cancers (excluding breast cancer) that have a specific genetic change called a PIK3CA mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if taselisib can sh…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug LP-184 tested on tough cancers: hope for Late-Stage patients
Disease control OngoingThis study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…
Phase: PHASE1, PHASE2 • Sponsor: Lantern Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental cell therapy for advanced gynecological cancers halted before start
Disease control TerminatedThis study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Tiny paclitaxel particles aim to hit tumors harder
Disease control OngoingThis early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for advanced cancer? ZG005 drug trial begins
Disease control OngoingThis phase II trial tests a new biologic drug called ZG005 in 50 adults with advanced solid tumors that have not responded to or are not suitable for standard treatments. Participants receive ZG005 by IV every three weeks. The study measures how many tumors shrink and tracks side…
Phase: PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Promising drug for immunotherapy side effects never tested: trial withdrawn
Disease control TerminatedThis phase II trial aimed to test the drug itacitinib in people with severe side effects from cancer immunotherapy that did not get better with steroids. The goal was to see if itacitinib could calm the overactive immune response causing these side effects. However, the study was…
Phase: PHASE2 • Sponsor: Douglas Johnson • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to boost immunotherapy in Hard-to-Treat cancers
Disease control OngoingThis study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody drug shows promise in fighting advanced cancers
Disease control OngoingThis Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and …
Phase: PHASE2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug duo takes on advanced cancers in early trial
Disease control OngoingThis study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody takes aim at Hard-to-Treat cancers
Disease control OngoingThis Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…
Phase: PHASE2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can freezing ovarian tissue help girls have babies later?
Disease control OngoingThis study offers girls from birth to age 17 the chance to freeze their ovarian tissue before medical treatments that could harm their fertility, such as chemotherapy or radiation. The tissue is removed surgically and stored. Later, if they want to have children, the tissue can b…
Phase: NA • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New cancer drug ALK-N001 enters early human testing
Disease control TerminatedThis early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…
Phase: PHASE1 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill targets gene flaws in hard-to-treat bile duct cancer
Disease control OngoingThis study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…
Phase: PHASE1, PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill shows promise against Hard-to-Treat RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control OngoingThis early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…
Phase: PHASE1 • Sponsor: University Hospital, Geneva • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Stem cell study to prevent transplant complications pulled before start
Disease control TerminatedThis study aimed to see if a special type of stem cell (hAESC) could safely prevent acute graft-versus-host disease in people receiving a stem cell transplant for blood cancer. It was designed for adults at high risk of this complication. However, the study was withdrawn before a…
Phase: PHASE1 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Bacteria bombs target stubborn tumors in new cancer combo trial
Disease control OngoingThis study tests a special bacteria (Clostridium novyi-NT) injected directly into tumors, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. The bacteria are designed to break down tumor cells f…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Cancer patients get continued access to promising drug
Disease control OngoingThis study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a probiotic help stem cell transplant recovery?
Disease control OngoingThis early-phase trial tests whether a probiotic called CBM588 is safe and can improve outcomes in 36 patients who have received a donor stem cell transplant. The probiotic aims to increase healthy gut bacteria and reduce gut-related side effects like diarrhea and colon inflammat…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Parent stem cells offer new hope for kids with blood cancer
Disease control OngoingThis study tests a new way to do stem cell transplants for 20 children with blood cancers or myelodysplasia who don't have a perfect donor match. Doctors remove certain immune cells from a parent's partially matched stem cells before transplant to help the new cells grow faster a…
Phase: PHASE1, PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New oral drug shows promise in early cancer trial
Disease control OngoingThis early-stage trial tests an experimental drug called LY3200882, taken orally, in people with solid tumors. The main goal is to check safety and find the right dose. Some participants also receive other cancer treatments like chemotherapy or radiation. The study involves 223 a…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Keytruda takes on genetic weak spots in advanced tumors
Disease control OngoingThis phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New Two-Drug immune attack launched against tough cancers
Disease control OngoingThis early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…
Phase: PHASE1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Precision radiation may boost second stem cell transplants for relapsed blood cancers
Disease control TerminatedThis early-stage trial tests a precise type of radiation (IMTMI) given with chemotherapy before a second donor stem cell transplant for people with advanced blood cancers that have returned. The goal is to find the safest dose and see if it can reduce side effects and prevent the…
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New immunotherapy combo tested for incurable cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or together with standard chemotherapy in people with advanced solid tumors that cannot be cured. The main goal is to find the highest safe dose that does not cause severe side effects. About 153 partici…
Phase: PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for advanced cancer? early trial of 3D185 begins
Disease control OngoingThis early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…
Phase: PHASE1 • Sponsor: 3D Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cancer drug ASTX660 tested in patients with no other options
Disease control OngoingThis study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…
Phase: PHASE1, PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can an enzyme shield the gut during transplant recovery?
Disease control OngoingThis study tests an oral enzyme called SYN-004 in adults who have received a stem cell transplant and need intravenous antibiotics for fever. The enzyme is designed to break down antibiotics in the gut, protecting the natural bacteria there. Researchers will check safety, whether…
Phase: PHASE1, PHASE2 • Sponsor: Theriva Biologics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New immune cell therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for young sarcoma patients: experimental drug combo targets tough tumors
Disease control TerminatedThis study tests a new drug called PEN-866, which stays in tumor cells longer than normal cells, combined with two standard chemotherapy drugs (vincristine and temozolomide). It is for people aged 12 to 39 with sarcomas (Ewing sarcoma or rhabdomyosarcoma) that have returned or no…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug HRS-6209 tested in advanced cancer patients
Disease control OngoingThis early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Two-Antibody combo takes on advanced cancers
Disease control OngoingThis study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…
Phase: PHASE1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug IBI363 aims to supercharge immune system against tough cancers
Disease control OngoingThis early-phase trial tests IBI363, a drug designed to both stimulate immune cells and block a cancer defense, in about 40 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goal is to find a safe dose and check for side effec…
Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New targeted therapy shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…
Phase: PHASE1, PHASE2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New mRNA vaccine shows promise in fighting solid tumors
Disease control OngoingThis early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New liposomal drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug E7386 tested for tough cancers
Disease control OngoingThis early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New pill shows promise against lung cancer in early trial
Disease control OngoingThis study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New immune drug shows promise in early trial for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …
Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cancer combo aims to supercharge immune attack on tumors
Disease control OngoingThis early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…
Phase: PHASE1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cell combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…
Phase: PHASE1 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Triple-Drug cocktail aims to keep lung cancer at bay
Disease control OngoingThis study tests a combination of three drugs—niraparib, temozolomide, and atezolizumab—in people with advanced solid tumors or extensive-stage small cell lung cancer. The goal is to find the best dose and see if the combination works better than atezolizumab alone as maintenance…
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug combination (E7389 liposomal formulation plus nivolumab) in 125 people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study is for people …
Phase: PHASE1, PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug ST101 takes on Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…
Phase: PHASE1, PHASE2 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Hitchhiking drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…
Phase: PHASE1 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for advanced tumors: experimental drug JSKN003 enters human trials
Disease control OngoingThis study tests an experimental drug called JSKN003 in Chinese adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial has two parts: first, finding the safest dose, and then expanding to see how well the drug shrinks tumors. About 725 parti…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail may tame deadly transplant complication
Disease control OngoingThis study tests a new combination of three drugs (cyclophosphamide, abatacept, and tacrolimus) given at lower doses to prevent graft-versus-host disease (GVHD) in 27 adults receiving a stem cell transplant from a half-matched donor. GVHD is a serious condition where donor cells …
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for advanced tumors? first human trial of SHR-4712 begins
Disease control OngoingThis early-stage study tests a new drug called SHR-4712 in 15 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and how the body processes it. Participants receive the drug until their disease gets worse or …
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug candidate targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called FDA018-ADC in about 78 adults with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to find a safe dose and check for side effects, while also seeing if t…
Phase: PHASE1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug SH006 tested in patients with advanced solid tumors
Disease control OngoingThis early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…
Phase: PHASE1 • Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New cell therapy aims to boost cancer fight
Disease control OngoingThis early-stage study tests a new treatment called ACIT-1, which uses donated immune cells to help fight cancer. About 34 adults with pancreatic or other cancers will receive one of four doses to find the safest and most effective dose. The goal is to see if the therapy can safe…
Phase: PHASE1, PHASE2 • Sponsor: Cancer Vaccines Limited • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for Hard-to-Treat cancers: NUV-1511 enters human trials
Disease control OngoingThis study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…
Phase: PHASE1, PHASE2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called BT7480, given alone or with another drug (nivolumab), in 200 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. It is an early-stage t…
Phase: PHASE1, PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New antibody combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tests a new antibody called BYON4228, given alone or with the immunotherapy drug pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study includes only 7 participants and aims to check safety, side effect…
Phase: PHASE1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…
Phase: PHASE1, PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cancer cocktail aims to rev up immune system against tumors
Disease control OngoingThis early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…
Phase: PHASE1, PHASE2 • Sponsor: Indaptus Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug trial hopes to shrink Hard-to-Treat tumors
Disease control OngoingThis early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …
Phase: PHASE1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New targeted drug aims to fight hard-to-treat bladder cancers
Disease control OngoingThis study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…
Phase: PHASE1, PHASE2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New pill combo aims to tame Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug combo shows promise in early cancer trial
Disease control OngoingThis early-stage study tests two experimental immunotherapy drugs, ABBV-927 and ABBV-181, in people with advanced solid tumors that have not responded to other treatments. The main goal is to find the safest dose and understand how the drugs move through the body. About 163 parti…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental antibody ADG206 targets Hard-to-Treat cancers in first human trial
Disease control OngoingThis early-phase study tests a new drug called ADG206 in 14 people with advanced solid tumors that have not responded to standard treatments. ADG206 is an antibody designed to activate the immune system by targeting CD137, a protein on immune cells. The main goals are to check sa…
Phase: PHASE1 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New personalized cancer vaccine shows promise in early trial
Disease control OngoingThis early-phase trial tests a personalized oral DNA cancer vaccine (NECVAX-NEO1) given alongside standard immunotherapy drugs in 20 adults with solid tumors. The vaccine is designed to target unique markers on each patient's cancer. The study aims to check safety and whether the…
Phase: PHASE1, PHASE2 • Sponsor: NEC Bio B.V • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New oral drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can a psoriasis drug stop transplant rejection?
Disease control OngoingThis phase II trial tests whether the drug ustekinumab (Stelara) can prevent acute graft-versus-host disease (GVHD) in 116 adults receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. Ustekinumab aims to calm this immune…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called DM919, alone or with pembrolizumab, in 160 adults with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe and effective dose and see if it can shrink tumors. Participants receive the drug by …
Phase: PHASE1 • Sponsor: D2M Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Immune test could personalize CMV prevention in transplant patients
Disease control OngoingThis study tests whether a CMV-specific T cell immunity test can help doctors decide how long to give letermovir to prevent late CMV infection after a stem cell transplant. About 250 adults with blood cancers who had a first transplant will take part. The goal is to see if using …
Phase: PHASE3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New pill takes on Hard-to-Treat cancers in first human trial
Disease control OngoingThis early-stage trial tests an experimental oral drug called PRJ1-3024 in 39 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may s…
Phase: PHASE1 • Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New antibody TST001 takes on stomach and pancreatic cancers
Disease control OngoingThis trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two experimental drugs, BAT8008 and BAT1308, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow cancer growth. About 112 participants …
Phase: PHASE1, PHASE2 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for kids with tough cancers: neratinib trial underway
Disease control OngoingThis study tests the safety and effectiveness of neratinib, a targeted cancer drug, in children whose solid tumors, brain tumors, lymphoma, or leukemia have come back or not responded to standard treatments. The drug is taken by mouth daily in 28-day cycles. The main goal is to f…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug shows promise for rare childhood cancers
Disease control OngoingThis study tests a drug called larotrectinib in children and young adults (up to age 30) with certain cancers that have a specific genetic change called a TRK fusion. The goal is to see if the drug can shrink solid tumors or control leukemia that has returned. The drug works by b…
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a personalized cell therapy called TBI-1301 for people with advanced solid tumors that express a protein called NY-ESO-1. Patients' own T cells are collected, genetically modified in a lab to better recognize and attack cancer cells, and then infused …
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New Pill-Infusion combo takes on Hard-to-Treat cancers
Disease control OngoingThis study tests a new oral drug called C019199 combined with an immunotherapy drug, sintilimab, in people with advanced solid tumors that no longer respond to standard treatments. The trial involves 155 participants and aims to check safety, find the right dose, and see if the c…
Phase: PHASE1, PHASE2 • Sponsor: Fujian Haixi Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Virus injection takes on Hard-to-Treat cancers in early trial
Disease control ENROLLING_BY_INVITATIONThis early study tests a single injection of a modified virus (BioTTT001) directly into tumors in 12 adults with advanced solid cancers that have not responded to standard treatments. The virus is designed to infect and kill cancer cells while also boosting the immune system. The…
Phase: PHASE1 • Sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental vaccine trains immune system to fight Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a personalized vaccine made from a patient's own immune cells, designed to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given along with chemotherapy and two immunotherapy drugs. The study includes 9 adults with advanced s…
Phase: PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Supercharged immune cells take on advanced cancers in tiny trial
Disease control OngoingThis phase 2 trial tests a new approach for people with advanced cancers that have not responded to other treatments. Doctors take a patient's own white blood cells, genetically modify them to recognize a protein called NY-ESO-1 found on some cancer cells, and infuse them back af…
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New cancer drug BR115 enters first human tests
Disease control TerminatedThis early-phase study tests a new drug called BR115 in 120 people with advanced solid tumors that have not responded to other treatments. The main goal is to check safety and find the right dose. Participants receive the drug weekly after an initial two doses, and the study moni…
Phase: PHASE1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New antibody drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called MHB039A, a bispecific antibody, in 196 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective. Participants receive the drug and are monitored for side effects and t…
Phase: PHASE1, PHASE2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Protein power: new study tests drink to fight muscle loss in chemo patients
Disease control ENROLLING_BY_INVITATIONThis study looks at whether a high-protein nutritional drink can help cancer patients aged 40 and older maintain muscle strength and feel less tired during chemotherapy. Participants with early signs of muscle loss will be randomly assigned to receive either the drink plus nutrit…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental virus injected into tumors shows early promise, but trial on hold
Disease control TerminatedThis early-stage trial tests a modified herpes virus (BS006) that is injected directly into tumors to kill cancer cells and activate the immune system. It involves 29 adults with advanced solid tumors like melanoma or breast cancer. The study is currently suspended, and its main …
Phase: PHASE1 • Sponsor: Binhui Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New pill tested for hard-to-treat cancers
Disease control OngoingThis early-stage study tests a new tablet called BB3008 in about 42 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body processes the drug. Participants take the tablet by m…
Phase: PHASE1 • Sponsor: Broadenbio Ltd., Co. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New Antibody-Drug conjugate targets advanced solid tumors in early trial
Disease control OngoingThis study tests a new drug called MHB036C, an antibody-drug conjugate, in 200 adults with advanced solid tumors. The trial has two phases: first to find the safest dose, then to see how well it works. Researchers will monitor side effects and measure drug levels in the blood.
Phase: PHASE1, PHASE2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug BT5528 targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…
Phase: PHASE1, PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental drug ARRY-614 paired with immunotherapy shows promise in early cancer trial
Disease control OngoingThis study tests an experimental drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors, including lung, head and neck, kidney, and skin cancers. The first part of the trial finds the safest dose, …
Phase: PHASE1, PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo tested for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new experimental drug called GSK6097608, given alone or with other cancer medicines, in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Abo…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for Hard-to-Treat cancers? early trial of TTX-MC138 begins
Disease control OngoingThis early-phase trial tests a new drug called TTX-MC138 in 16 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink or stabilize tumors. It is an open-label study, meaning everyone know…
Phase: PHASE1, PHASE2 • Sponsor: TransCode Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New Dual-Action antibody takes on advanced cancers
Disease control OngoingThis early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have spread or come back. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effect…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
AI that reads faces could spot hidden distress in cancer patients
Diagnosis ENROLLING_BY_INVITATIONThis trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can a new PET tracer reveal hidden immune clues in tumors?
Diagnosis TerminatedThis phase I trial tests an experimental imaging agent called 64Cu-DOTA-pembrolizumab, which is designed to attach to PD1, a protein on immune cells that often cluster around tumors. By injecting this agent and then performing a PET scan, researchers hope to see where these immun…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a new tracer light up cancer growth?
Diagnosis OngoingThis trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…
Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a new PET tracer spot tumors more clearly?
Diagnosis TerminatedThis trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…
Sponsor: Jinling Hospital, China • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a new tracer light up tumors better than standard PET scans?
Diagnosis ENROLLING_BY_INVITATIONThis trial is testing an experimental imaging agent called [68Ga]Ga-ELI411, which is designed to bind to a protein (FAP) found in many solid tumors. The study will involve 18 adults with confirmed solid tumors who are already scheduled for a standard FDG-PET scan. Participants wi…
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
New scan could reveal tumor oxygen levels, guiding better cancer treatment
Diagnosis OngoingThis early-phase study tests how well a special PET-CT scan called FAZA can measure oxygen levels in solid tumors like breast, colorectal, and pancreatic cancers. About 25 participants will receive the FAZA tracer and undergo imaging to see if the results are consistent over time…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Aug 01, 2026 00:00 UTC
-
Finger-Prick test could replace needles for cancer blood monitoring
Diagnosis TerminatedThis study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …
Sponsor: Entia Ltd • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Can a simple ultrasound predict immunotherapy success?
Diagnosis TerminatedThis study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…
Phase: NA • Sponsor: Stanford University • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Could a routine blood test spot many cancers early?
Diagnosis OngoingThis study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…
Sponsor: Zhejiang Cancer Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
Hidden heart risk in cancer patients: simple ECG screening could save lives
Diagnosis OngoingThis study tests whether a simple 30-second ECG using a handheld device can find undiagnosed atrial fibrillation (an irregular heartbeat) in people aged 65 and older with cancer. About 500 participants will be randomly assigned to either get the quick screening or usual care. The…
Phase: NA • Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
New PET scan agent could predict cancer therapy success, but trial never started
Diagnosis TerminatedThis pilot study aimed to test whether a radioactive imaging agent called 68Ga-FAPI-46 could predict how well solid tumor patients respond to antibody therapy. The plan was to give 50 participants an injection of the agent, then perform a PET/CT scan and compare it to standard MR…
Phase: EARLY_PHASE1 • Sponsor: Eben Rosenthal • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Heart shield: diabetes drug may prevent Chemo-Induced cardiac damage
Prevention OngoingThis study tests whether empagliflozin, a drug used for diabetes, can prevent heart damage in cancer patients receiving strong chemotherapy (anthracyclines). About 220 adults with cancer but no prior heart failure will take either the drug or a placebo daily for 12 months. The go…
Phase: PHASE3 • Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Probiotics may shield cancer patients from Immunotherapy's gut woes
Prevention TerminatedThis study tests whether taking an over-the-counter probiotic (VSL#3® 450B) can prevent colitis (colon inflammation) and diarrhea in cancer patients receiving immunotherapy. Up to 45% of patients on these drugs develop this side effect. The trial enrolls adults with solid tumors …
Phase: NA • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
Donor vaccine may shield transplant patients from dangerous virus
Prevention OngoingThis early-phase study tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can prevent the virus from causing problems in blood cancer patients after a transplant. About 34 donor-recipient pairs are taking part. The vaccine is given to the donor before stem c…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
Probiotic shows promise in preventing Life-Threatening transplant complication in kids
Prevention OngoingThis study tests whether a probiotic called Lactobacillus plantarum can prevent a serious complication called graft-versus-host disease (GvHD) in the gut of children receiving a donor stem cell transplant. About 173 children with blood cancers or other conditions are taking the p…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Prevention
Last updated Jun 27, 2026 07:54 UTC
-
Pen and paper: a new weapon against blood cancer stress?
Symptom relief OngoingThis study explores whether an online expressive writing workshop can boost mental wellness in young adults (ages 18-39) with blood cancer. One hundred participants will either start the workshop right away or wait four weeks. Everyone takes surveys about their mood and stress ov…
Phase: NA • Sponsor: Blood Cancer United • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Can a smartphone app help young cancer survivors get moving and improve their quality of life?
Symptom relief OngoingThis study tests a 12-week mobile health program for 304 young adult cancer survivors (ages 18-39) who finished treatment within the last 5 years. The program combines social support and mindfulness training to encourage moderate-to-vigorous physical activity. The goal is to see …
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New online program aims to ease pain for cancer survivors
Symptom relief OngoingThis study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Cancer breathlessness study: can opioids help you walk easier?
Symptom relief OngoingThis study tests if fast-acting opioids (fentanyl or morphine) can reduce shortness of breath during or after walking in 150 cancer patients who already take strong painkillers. Participants will take the drug or a placebo before a short walk test, and researchers will measure ch…
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a sugar pill you know is fake fight cancer fatigue?
Symptom relief OngoingThis study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Virtual reality headsets may calm cancer patients before radiation
Symptom relief ENROLLING_BY_INVITATIONThis trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…
Phase: NA • Sponsor: Oman Ministry of Health • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
A digital bridge: could an online pathway ease depression in cancer care?
Symptom relief OngoingThis study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…
Phase: NA • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Mind over body: new film series aims to boost wellbeing in young cancer survivors
Symptom relief OngoingThis study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …
Phase: NA • Sponsor: King's College London • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Veterans with cancer get help discussing End-of-Life wishes in group sessions
Symptom relief OngoingThis study tests whether group education sessions can help veterans with newly diagnosed cancer discuss their goals of care and complete advance directives. Fifty veterans will attend two virtual or in-person sessions led by a trained health educator. Researchers will check if th…
Phase: NA • Sponsor: VA Palo Alto Health Care System • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Can two existing drugs help cancer patients ditch steroids?
Symptom relief OngoingThis study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…
Phase: PHASE2 • Sponsor: Columbia University • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Heart help for cancer survivors: exercise and diet study launches
Symptom relief OngoingThis study looks at whether exercise training and dietary counseling can help cancer survivors who have heart failure. About 85 participants will either receive usual care or join a program with exercise three times a week and low-salt diet guidance. The goal is to see if this li…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Can a lay coach ease the burden for cancer caregivers?
Symptom relief OngoingThis study tests a program called ENABLE Cornerstone, where specially trained lay coaches provide support to family caregivers of people with advanced cancer. The coaches help caregivers manage stress, improve coping skills, and plan for the future through phone or in-person sess…
Phase: PHASE3 • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Maine cancer patients get free groceries and coaching in new study
Symptom relief OngoingThis study is testing whether giving cancer patients in Maine free, medically tailored groceries plus nutrition counseling can improve their diet and well-being. One hundred adults with any stage or type of cancer will be split into three groups: one gets groceries and counseling…
Phase: NA • Sponsor: Yale University • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Faith and mindfulness join forces to heal black cancer survivors
Symptom relief ENROLLING_BY_INVITATIONThis trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Can a smartphone app ease cancer Survivors' stress? new trial aims to find out
Symptom relief OngoingThis study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …
Phase: NA • Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Can a calming drug combo bring clarity to cancer patients?
Symptom relief OngoingThis study looks at whether adding lorazepam to haloperidol can better reduce delirium (sudden confusion and agitation) in people with advanced cancer who are in a palliative care unit. About 93 participants will receive either haloperidol alone or with lorazepam, and their level…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Can writing about cancer help young survivors heal?
Symptom relief OngoingThis study tests whether a virtual group writing program can improve quality of life for young adults who survived cancer. Thirty survivors aged 18-39, diagnosed 1-5 years ago, will write about their cancer experiences in a group setting. The goal is to see if this simple, access…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
New study tests two ways to ease cancer symptoms and boost Well-Being
Symptom relief OngoingThis study looks at whether a new approach to managing symptoms can improve quality of life for cancer patients who are starting palliative care. About 208 adults from Pennsylvania took part. Researchers compared two different methods of symptom control to see which one helps pat…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Virtual reality offers escape for bone marrow transplant patients
Symptom relief OngoingThis study tests whether using virtual reality (VR) can improve symptoms like pain, anxiety, and fatigue in patients receiving a bone marrow transplant. About 28 adults will be randomly assigned to either VR sessions or standard care during their hospital stay. The goal is to see…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Sniffing away sickness: essential oils tested for chemo nausea
Symptom relief TerminatedThis trial explores whether inhaling essential oils like peppermint, lavender, or ginger can help reduce nausea and anxiety in cancer patients receiving chemotherapy infusions. Current anti-nausea drugs often cause constipation and fatigue, so researchers are looking for gentler …
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Can a steroid and exercise beat cancer fatigue?
Symptom relief OngoingThis study tests whether adding the steroid dexamethasone to a physical activity program helps reduce severe fatigue in people with advanced cancer. About 99 participants will take the drug or a placebo while doing strength and walking exercises. The goal is to see if the combina…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Testosterone gel trial aims to beat cancer fatigue in older men
Symptom relief OngoingThis study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…
Phase: PHASE2 • Sponsor: Seattle Institute for Biomedical and Clinical Research • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Could a single doctor visit reduce cancer distress?
Symptom relief ENROLLING_BY_INVITATIONThis study explores whether a structured survivorship care visit, conducted early in cancer treatment, can help reduce psychological distress and improve quality of life. Adults with any type of cancer who report significant distress will meet with a physician assistant to discus…
Phase: NA • Sponsor: Ellis Medicine • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Green tea extract tested to fight frailty in older cancer survivors
Symptom relief TerminatedThis phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Money worries in cancer care: new study tests financial coaching to ease the burden
Symptom relief OngoingThis study tests whether a financial navigation and counseling program (CostCOM) can help newly diagnosed cancer patients who are struggling with costs or basic needs like food and housing. About 91 patients will either get the program, educational materials, or usual care. The g…
Phase: NA • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could an herbal patch ease pain after cancer?
Symptom relief OngoingThis study tests whether an over-the-counter herbal pain patch, called Tibetree Pain Relieving Plaster, can reduce muscle and joint pain in people who have finished active cancer treatment. Sixty-eight cancer survivors will apply either the active patch or a placebo patch to thei…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New combo targets debilitating fatigue in advanced cancer patients
Symptom relief OngoingThis study tests whether a drug called anamorelin, combined with physical activity and nutritional counseling, can reduce severe fatigue in people with advanced solid tumors that have spread or returned. About 129 participants with incurable cancers and high fatigue levels will r…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to ease agitated delirium in dying cancer patients
Symptom relief OngoingThis study looks at how well two drugs, haloperidol and lorazepam, can control severe agitation and confusion (delirium) in people with advanced cancer who are in palliative care. About 110 patients will be enrolled to compare different drug approaches. The goal is to improve com…
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New support program aims to ease emotional burden of advanced cancer
Symptom relief ENROLLING_BY_INVITATIONThis pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…
Phase: NA • Sponsor: Ponce Medical School Foundation, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
Cancer survivors find hope in Peer-Led Self-Management program
Symptom relief OngoingThis study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …
Phase: NA • Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
Can a common steroid help cancer patients breathe easier?
Symptom relief OngoingThis study tested whether the steroid dexamethasone can reduce shortness of breath (dyspnea) in people with cancer. About 135 cancer patients with moderate to severe breathing difficulty took part. Researchers measured changes in their breathlessness over one to two weeks to see …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Writing away the pain: new study tests expressive helping for cancer survivors
Symptom relief OngoingThis study looks at whether a writing program called Expressive Helping can improve emotional well-being for Chinese American cancer survivors. About 108 people who finished cancer treatment within the last 5 years will write about their experiences. The goal is to see if this ap…
Phase: NA • Sponsor: New York University • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New telehealth program aims to ease emotional burden of advanced cancer
Symptom relief ENROLLING_BY_INVITATIONThis study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…
Phase: NA • Sponsor: Ponce Medical School Foundation, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New app aims to boost Well-Being in cancer patients
Symptom relief OngoingThis study tests a digital program called MINDSET designed to help newly diagnosed cancer patients cope better with treatment. 440 participants will use either the program or a control, and complete questionnaires and blood tests. The goal is to see if the program improves physic…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Can a common steroid ease cancer symptoms? new trial investigates
Symptom relief OngoingThis phase 2 trial tests whether dexamethasone, a steroid, can help control fatigue, pain, nausea, and other symptoms in 132 adults with advanced solid tumors. Participants take the drug or a placebo by mouth twice daily for 14 days. The main goal is to see if symptoms improve, m…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
No more hospital trips? video nutrition counseling tested for cancer weight loss
Symptom relief OngoingThis study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…
Phase: NA • Sponsor: King Edward Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New study aims to tackle loneliness in cancer survivors
Symptom relief ENROLLING_BY_INVITATIONThis study tests a 9-week virtual program that helps cancer survivors build social connections and reduce loneliness. Participants work one-on-one with a facilitator to create a personalized action plan. The goal is to see if this approach improves well-being and quality of life.
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Holy Qur'an or music: which helps kids on chemo sleep better?
Symptom relief OngoingThis study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…
Phase: NA • Sponsor: Rawand Shafeeq Ali • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to beat Cancer-Related insomnia
Symptom relief OngoingThis phase 2 trial tests whether combining cognitive behavioral therapy, a stimulant (methylphenidate), melatonin, and light therapy can improve sleep in cancer patients. About 68 patients currently on cancer treatment who have sleep problems will participate. The study measures …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Talking hope: new therapy aims to lift spirits of cancer patients during radiation
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a special type of counseling called hope-focused motivational interviewing can improve hope, self-confidence, and self-compassion in cancer patients who are getting radiation therapy. About 46 adults with early-stage cancer will be randomly assigned to re…
Phase: NA • Sponsor: Saglik Bilimleri Universitesi • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Virtual reality headsets tested to calm cancer patients during painful procedures
Symptom relief TerminatedThis trial tests whether wearing a virtual reality headset during a bone marrow biopsy or lumbar puncture can reduce pain and anxiety in cancer patients. About 60 participants will use the headset while receiving standard care. The study is currently suspended, so results are pen…
Phase: NA • Sponsor: University of Southern California • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Simple relaxation technique may ease stress for blood cancer patients
Symptom relief OngoingThis study tests whether teaching progressive muscle relaxation and providing psychoeducation can lower stress and increase hope in adults with blood cancers like leukemia or lymphoma. About 75 participants will learn these techniques and report their stress and hope levels. The …
Phase: NA • Sponsor: Necmettin Erbakan University • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Virtual reality could ease stress of bone marrow transplants
Symptom relief OngoingThis study tests whether a virtual reality (VR) program can help people undergoing bone marrow transplants cope with stress and improve their quality of life. About 80 adult patients with blood cancer will be randomly assigned to either receive the VR program plus usual care, or …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Can a virtual sleep program help cancer survivors beat insomnia?
Symptom relief OngoingThis study aims to find the best way to deliver cognitive behavioral therapy for insomnia (CBT-I) to cancer survivors who have chronic sleep problems. Researchers are comparing individual vs. group sessions and whether adding booster sessions helps. The goal is to create an effec…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Magic mushroom compound tested for Cancer-Related depression
Symptom relief OngoingThis study tests whether up to two doses of psilocybin (the active ingredient in magic mushrooms) can safely reduce depression in adults who have both cancer and major depressive disorder. About 56 participants will receive either psilocybin or a placebo in a first session, and t…
Phase: PHASE2 • Sponsor: Sunstone Medical • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Fitbit and app aim to boost activity in cancer survivors
Symptom relief OngoingThis study looks at whether personalized exercise plans delivered through a Fitbit and a smartphone app can help cancer survivors become more physically active. Researchers will track steps, weight, quality of life, and emotional well-being in 160 adult survivors who have finishe…
Phase: NA • Sponsor: The University of Tennessee, Knoxville • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
New toolkit aims to boost recovery for older cancer surgery patients
Symptom relief OngoingThis study tests a pre-surgical toolkit (OPTI-Surg) designed to help older cancer patients recover more quickly after major surgery. The toolkit provides recommendations before surgery to improve physical function and reduce complications. About 325 participants with various canc…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Can an iPad program help older cancer patients stay strong?
Symptom relief OngoingThis study looks at whether an 8-week digital program called COBRA, which includes balance and resistance exercises, is safe and practical for older adults with cancer. The program is delivered via an iPad with video calls. Researchers will track how many participants stick with …
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Fitbit for cancer care: new study tests remote exercise monitoring
Symptom relief OngoingThis study looks at whether using activity trackers and a phone app can help people with cancer reach their exercise goals during treatment. Twenty-five participants will wear the trackers for three months. The goal is to see if this approach is practical and helpful for both pat…
Phase: NA • Sponsor: Shirley Ryan AbilityLab • Aim: Symptom relief
Last updated Jun 27, 2026 12:10 UTC
-
Can online yoga help cancer survivors sleep better?
Symptom relief OngoingThis study tests whether virtual yoga classes can help cancer survivors who have trouble sleeping. About 42 survivors will either take 8 virtual yoga sessions over 4 weeks or continue their usual care. Researchers will measure changes in insomnia and sleep quality to see if the o…
Phase: NA • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Can yoga and relaxation help young cancer survivors? new study tests a Stress-Busting program
Symptom relief OngoingThis study tests a group program called the Relaxation Response Resiliency Program (3RP-AYA) for adolescents and young adults who finished cancer treatment in the last 5 years. The program uses mind-body techniques like imagery, relaxation, and yoga to reduce stress and build res…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Smartphone app aims to ease suffering for advanced cancer patients
Symptom relief OngoingThis study tests whether a mobile app called SUPPORT+ can improve quality of life for adults with advanced cancer who are no longer receiving anticancer treatment. Participants use the app to report symptoms weekly, get self-care tips, and receive nurse follow-up if symptoms are …
Phase: NA • Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Spine adjustments tested as fatigue fix for cancer survivors
Symptom relief TerminatedThis pilot study explores whether chiropractic adjustments to the upper neck can reduce chronic fatigue in adults who have finished cancer treatment. About 40 cancer survivors who are currently cancer-free will receive either immediate or delayed chiropractic care for 6 to 12 wee…
Phase: NA • Sponsor: Life University • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
New program aims to ease financial burden for families of young cancer patients
Symptom relief ENROLLING_BY_INVITATIONThis study tests a program that helps caregivers of teens and young adults (ages 15-26) with cancer find resources for financial and social needs. About 60 caregiver-patient pairs will take part. The goal is to see if this support reduces stress and improves well-being.
Phase: NA • Sponsor: Columbia University • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Cash for cancer care: $1,000 a month trial aims to ease financial burden
Symptom relief OngoingThis study gives 250 advanced cancer patients $1,000 each month for a year to see if it reduces financial stress and improves quality of life. Participants also complete surveys every three months. The goal is to learn whether extra income can help patients stick to treatments an…
Phase: NA • Sponsor: Meredith Doherty, PhD, LCSW • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can mindfulness ease cancer stress for latino families?
Symptom relief OngoingThis study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
New meditation program aims to ease cancer symptoms in black patients
Symptom relief OngoingThis study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can a smartphone app help rural cancer patients beat the odds?
Symptom relief OngoingThis study tests an electronic symptom management system called Nurse AMIE in 344 people with stage 3 or 4 cancer living in rural areas. The goal is to see if using the system helps them live longer and improves their quality of life. Participants use the system to report symptom…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Knee pain study for cancer patients pulled before starting
Symptom relief TerminatedThis study aimed to see if a special needle treatment (ultrasound-guided neuromodulation) could reduce front knee pain in cancer patients better than standard painkillers. It was planned for adults aged 18-65 with knee pain related to cancer. However, the study was withdrawn befo…
Phase: NA • Sponsor: Universidad Europea de Canarias • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Pain relief study for cancer patients withdrawn before starting
Symptom relief TerminatedThis trial was designed to see if nerve stimulation techniques could reduce lower limb pain in cancer patients better than medication. It was withdrawn before enrolling any participants, so no results are available. The study would have compared ultrasound-guided percutaneous neu…
Phase: NA • Sponsor: Universidad Europea de Canarias • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Simple breathing trick may calm chemo nausea
Symptom relief OngoingThis study tests whether a relaxation breathing exercise can help reduce nausea and vomiting caused by chemotherapy in people with blood cancers. Sixty-eight patients are split into two groups: one does breathing exercises three times a day plus standard care, the other gets stan…
Phase: NA • Sponsor: Marmara University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
New online tool aims to ease Family-Building decisions for young cancer survivors
Symptom relief OngoingThis study tests a web-based decision aid called 'Roadmap to Parenthood' for young women who have completed cancer treatment and are thinking about having children. The tool provides information and planning support to help them make informed choices. Researchers will measure whe…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New online program aims to restore sexual health in young cancer survivors
Symptom relief OngoingThis study compares two brief online educational programs for young women (ages 19-49) who have finished cancer treatment and are dealing with sexual health issues. Participants join video sessions and report changes in sexual function and emotional well-being. The goal is to fin…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Could a simple referral to palliative care ease End-of-Life suffering for cancer patients?
Symptom relief OngoingThis study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves…
Phase: NA • Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Music may soothe nerves during bone marrow biopsy
Symptom relief OngoingThis phase III trial tests whether listening to music during a bone marrow biopsy or aspiration can lower anxiety. About 113 adults with blood cancers will be randomly assigned to either receive standard care or also listen to music during the procedure. Researchers will measure …
Phase: PHASE3 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Exercise boosts quality of life in cancer patients, study finds
Symptom relief OngoingThis study looks at whether a supervised exercise program in community settings can improve quality of life and reduce fatigue in adults with cancer. 492 participants, including survivors and those on active treatment, will take part in group exercise sessions. Researchers will t…
Sponsor: University of Castilla-La Mancha • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Can acupuncture with electricity ease cancer brain fog and fatigue?
Symptom relief OngoingThis study tests whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help cancer patients and survivors with clusters of symptoms like memory problems, fatigue, insomnia, anxiety, and depression. Seventy participants will receive either real electro…
Phase: NA • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Antidepressant drug could fight cancer fatigue
Symptom relief OngoingThis phase 3 trial tests whether bupropion, a drug used for depression and smoking cessation, can reduce fatigue in 422 cancer survivors. Participants have stable disease or no evidence of cancer and report moderate to severe fatigue. They receive either bupropion or a placebo, a…
Phase: PHASE3 • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Which method helps cancer patients best? new study tests palliative care delivery
Symptom relief OngoingThis study looks at two different methods—a Virtual Learning Collaborative or Technical Assistance—for delivering a palliative care program called ENABLE to people with advanced cancer and their caregivers. Palliative care focuses on relieving symptoms, reducing stress, and impro…
Phase: NA • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Texts and trackers: new study aims to get young cancer survivors moving
Symptom relief OngoingThis study tests whether a mobile health program can help adolescents and young adults (ages 15-39) who finished cancer treatment become more physically active. Participants get a personalized activity plan, a fitness tracker, access to an online survivor community, and motivatio…
Phase: NA • Sponsor: AHS Cancer Control Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
New program helps cancer patients and caregivers talk through tough emotions
Symptom relief OngoingThis study tests a communication program for people with advanced cancer and their caregivers. The goal is to help them manage difficult emotions and talk about the patient's illness and treatment wishes. About 45 participants will take part, and the program is tailored for Latin…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Can a smartphone app boost quality of life for young cancer patients?
Symptom relief OngoingThis study tests whether a phone app called OnKO-Tips&Tricks can improve the quality of life for adolescents and young adults (ages 15-25) recently diagnosed with cancer. The app helps with daily check-ins, education, and connecting with a nurse coordinator. Researchers will comp…
Phase: NA • Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Can a natural supplement soothe chemo nerve damage?
Symptom relief OngoingThis phase II trial tests whether a natural supplement called PEA can relieve nerve pain, numbness, and tingling caused by chemotherapy in cancer patients. About 88 adults who have had nerve symptoms for at least 3 months after chemo will take PEA or a placebo for 8 weeks. The st…
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Can cancer patients get better care at home? MD anderson investigates
Knowledge-focused TerminatedThis study aims to understand the experiences of cancer patients who receive care at home through MD Anderson's Care and Monitoring at Home program. Researchers will use surveys to measure quality of life and gather feedback from up to 40 participants. The goal is to learn whethe…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Researchers dig into past data to uncover M7824's hidden side effects
Knowledge-focused OngoingThis study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
A simple screening program could transform cancer aftercare
Knowledge-focused OngoingThis trial tests whether a structured, nurse-led symptom screening program can increase the number of cancer survivors who are screened for distress and referred to supportive services. The program includes nurse training and regular feedback, and it will be rolled out across mul…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Massive study aims to uncover hidden triggers of blood cancers
Knowledge-focused ENROLLING_BY_INVITATIONThis study is collecting blood, bone marrow, and tissue samples from 5,000 people with blood cancers like leukemia and lymphoma. Researchers will analyze the samples to find genetic abnormalities that cause cancer cells to grow. The goal is to understand why these cancers develop…
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
500 cancer Patients' records reviewed to tame immunotherapy side effects
Knowledge-focused OngoingThis study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New tool lets young cancer patients speak up about symptoms
Knowledge-focused OngoingThis study tests whether a simple questionnaire, filled out by children and teens with cancer (and their caregivers) before and after a clinic visit, can help doctors better understand their symptoms. About 85 participants will use the tool during routine visits. The goal is to s…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Hidden risk: could opioid misuse be overlooked in cancer care?
Knowledge-focused TerminatedThis study aims to find out how often cancer patients treated with opioids for pain are at risk of misusing these medications. Researchers will use two screening questionnaires to assess misuse risk in 200 adult outpatients receiving opioids for cancer-related pain. The findings …
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
15-Year safety watch for cell therapy recipients
Knowledge-focused ENROLLING_BY_INVITATIONThis study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …
Phase: PHASE1 • Sponsor: USWM CT, LLC • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Gut bacteria may hold key to safer cancer immunotherapy
Knowledge-focused OngoingThis study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New study aims to perfect chemo dosing for cancer patients
Knowledge-focused OngoingThis study looks at whether a dye called iohexol can help doctors better calculate the dose of the chemotherapy drug carboplatin for cancer patients. The goal is to make sure patients get the right amount of drug to fight their cancer while reducing side effects. About 318 men wi…
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Cancer tissue bank study aims to unlock new treatment clues
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can a smartphone app get young cancer survivors moving? new study aims to find out.
Knowledge-focused OngoingThis study looks at whether a mobile health program combined with social media can help teens and young adults who survived childhood cancer become more physically active. About 387 participants will either use the program plus a fitness tracker or just the tracker alone. The goa…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
New study reveals hidden toll of Cancer-Related weight loss on families
Knowledge-focused OngoingThis study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Lab-Grown 3D tumors could help pick the right chemo for blood cancer patients
Knowledge-focused OngoingThis study uses bone marrow samples from 70 people with blood cancers to create 3D organoids—tiny lab-grown models that mimic the tumor's environment. Researchers will test different chemotherapy combinations on these organoids to see which kills the most cancer cells. The goal i…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Do blood thinners help or hurt when cancer meets a clot?
Knowledge-focused OngoingThis study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can natural remedies and cancer treatments mix safely? a new study investigates
Knowledge-focused OngoingThis study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…
Phase: NA • Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Cancer patients with COVID-19: new study tracks their journey
Knowledge-focused OngoingThis study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Chatbot could help families of kids with cancer understand genetic risks
Knowledge-focused ENROLLING_BY_INVITATIONThis study is testing whether a chatbot can help parents of children with cancer learn about genetic risks and decide whether to get tested themselves. The chatbot provides education and support as an alternative to speaking with a genetic counselor. The goal is to make it easier…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
Knowledge-focused TerminatedThis study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…
Sponsor: Entia Ltd • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Could a COVID-19 shot boost cancer immunotherapy? a massive study digs into the timing.
Knowledge-focused OngoingThis large observational study looks at whether getting an mRNA COVID-19 vaccine shortly before or after starting immune checkpoint inhibitor therapy is linked to longer survival in adults with cancer. Using data from nearly 100,000 patients in France, researchers are comparing t…
Sponsor: Groupe Hospitalier Pitie-Salpetriere • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Gene test could personalize cancer drug dosing
Knowledge-focused OngoingThis study looks at whether a broad genetic test (microarray PGx) can find more drug-gene interactions than the standard single-gene test in 120 adults with cancer who are about to receive chemotherapy. The goal is to see if this extra information could help doctors adjust drug d…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Can a simple home breathing test catch lung trouble early in transplant patients?
Knowledge-focused OngoingThis study follows 250 people who have had a donor stem cell transplant to see if respiratory viruses lead to a lung condition called bronchiolitis obliterans syndrome (BOS). Participants use a handheld device at home to measure lung function and provide nasal swabs and blood sam…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Blood cell collection could open door to CAR T-Cell therapy for leukemia and lymphoma patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
New DNA test aims to predict bloodstream infections in kids with cancer
Knowledge-focused OngoingThis study at St. Jude Children's Research Hospital is testing whether a next-generation DNA test can predict bloodstream infections in children and teens with cancer who are at high risk. Current methods often detect infections too late, leading to severe illness or death. The g…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Can a simple sheet of paper improve cancer care conversations?
Knowledge-focused OngoingThis study compares two different information sheets given to advanced cancer patients and their caregivers before a doctor visit. One sheet has sample questions to ask, the other has general information. The goal is to see which one helps patients and caregivers communicate bett…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Cancer Patients' pandemic struggles revealed in new study
Knowledge-focused OngoingThis study looks at how the COVID-19 pandemic impacted the well-being and quality of life of over 13,000 cancer patients and survivors. Researchers used questionnaires to gather information on experiences like exposure, isolation, and financial disruptions. The goal is to underst…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Artificial intelligence reads tissue samples in minutes to guide cancer surgery
Knowledge-focused OngoingThis study is developing an artificial intelligence model that can analyze frozen-section pathology images—tissue samples examined during surgery. The goal is to help pathologists quickly and accurately diagnose cancer while the patient is still in the operating room. Researchers…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New study tracks COVID-19 vaccine response in young cancer patients
Knowledge-focused OngoingThis study follows 549 children, teens, and young adults with cancer to see how their immune systems respond to COVID-19 vaccines. Researchers collect blood samples to measure protective antibodies. The goal is to learn how cancer and its treatment affect vaccine effectiveness, a…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Cancer and heart failure: a double burden under the microscope
Knowledge-focused OngoingThis study looks at how people with both cancer and heart failure feel day-to-day. Researchers will ask 100 participants about their symptoms and quality of life using simple questionnaires. No new treatments are tested—the goal is to better understand the challenges these patien…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Island hopping for cancer care: first study maps Survivors' journeys across six caribbean nations
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…
Sponsor: Vaughan A. Lewis Institute for Research and Innovation • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Pharmacist-Led lessons may cut infection risk in chemo patients
Knowledge-focused OngoingThis trial tests whether a pharmacist-led educational program helps cancer patients on high-risk chemotherapy better understand and follow neutropenic precautions—steps to prevent serious infections when white blood cell counts are low. About 300 adults with various cancers will …
Phase: NA • Sponsor: Jordan University of Science and Technology • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Could your workout history affect your Cancer's genes?
Knowledge-focused OngoingThis study creates a registry of cancer patients who have had their tumor genes analyzed. Participants fill out a 10-minute survey about their exercise habits before and after diagnosis. Researchers will look for connections between physical activity and genetic changes in tumors…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Smartwatches for cancer survivors: a new way to track symptoms?
Knowledge-focused OngoingThis study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…
Sponsor: Laura Longshaw • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Spirituality may be key to coping with blood cancer from day one
Knowledge-focused TerminatedThis study looks at how spirituality — personal beliefs, values, and meaning — influences adults recently diagnosed with blood cancers like lymphoma or leukemia, as well as their loved ones. Participants fill out three questionnaires about spiritual well-being, quality of life, a…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Can coaching caregivers improve cancer Decision-Making?
Knowledge-focused OngoingThis study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a simple card keep cancer patients safer?
Knowledge-focused OngoingThis study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a smart patch predict dangerous immune reactions in cancer treatment?
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Teens with cancer help improve symptom tracking tool
Knowledge-focused OngoingThis study tests a symptom questionnaire designed for teenagers with cancer. Researchers will interview 41 adolescents aged 13-17 to see if the survey accurately captures their symptoms. The goal is to improve how doctors understand and manage symptoms in young cancer patients.
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New platform aims to personalize cancer treatment for GI patients
Knowledge-focused OngoingThis study aims to create a comprehensive precision oncology platform at the Chinese University of Hong Kong to personalize drug therapy for 170 patients with advanced gastrointestinal cancers. Researchers will collect tumor samples for genetic sequencing and grow patient-derived…
Sponsor: Brigette Ma • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test may predict ICU death risk for cancer patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study examines whether a routine blood test called Mean Platelet Volume (MPV), taken when a cancer patient is admitted to the intensive care unit (ICU), can help predict their risk of dying. Researchers will review the medical records of 425 adult cancer patients who stayed …
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Cancer's hidden toll: young kids miss key social milestones
Knowledge-focused OngoingThis study looks at how cancer and its treatment impact social and emotional development in children aged 4 to 6. About 119 children with brain or solid tumors will complete questionnaires and tasks to measure social skills, thinking abilities, and play behavior. The goal is to u…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks cancer patients at home to improve care
Knowledge-focused OngoingThis study looks at a program where cancer patients report their symptoms from home using a computer or phone. A navigator helps manage those symptoms. The goal is to see if this approach improves patient care and reduces emergency visits. About 3,090 adults with cancer are takin…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Cancer immunotherapy may throw patients off balance – literally
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study at Mayo Clinic looks at how immunotherapy drugs affect balance and hearing in cancer patients. Researchers will test 50 adults before and during treatment to see if their vestibular (balance) system changes over a year. The goal is to better understand si…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Logbook study for stem cell patients pulled before start
Knowledge-focused TerminatedThis pilot study aimed to see if giving a logbook to patients hospitalized for a stem cell transplant could help reduce feelings of isolation and psychological stress. The study was withdrawn before enrolling any participants, so no results are available. It was planned at the Un…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Blood cancer chemo and adrenal risk study pulled before start
Knowledge-focused TerminatedThis study planned to check how often the adrenal glands stop working properly after chemotherapy in adults with blood cancers. It aimed to measure cortisol levels after a stimulation test. However, the study was withdrawn before any participants were enrolled, so no results are …
Phase: NA • Sponsor: Rennes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Keytruda immune response trial aims to unlock cancer clues
Knowledge-focused OngoingThis phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Blood cancer patients with drug allergies may get safer antibiotics thanks to new study
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how doctors and patients feel about a new approach to picking antibiotics for people with blood cancers who have a reported penicillin allergy. The goal is to understand what might make it easier or harder to use this approach in everyday hospital care. About …
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Cancer patients get help planning families in new study
Knowledge-focused OngoingThis study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists hunt for genetic clues in blood and urine to personalize lung cancer care
Knowledge-focused OngoingThis study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…
Phase: NA • Sponsor: University of Arkansas • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New web tool aims to help young cancer patients plan for family future
Knowledge-focused OngoingThis study tests a web-based tool called REFLECT, designed to help adolescent and young adult cancer patients learn about fertility and genetic risks for future children. Sixteen participants who have had cancer care at Moffitt Cancer Center will use the tool and rate how easy an…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Cancer patients' family talks about genetic surprises studied
Knowledge-focused OngoingThis study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Can a simple check spot hidden malnutrition in older cancer patients?
Knowledge-focused OngoingThis study looks at how well nutritional assessments can detect malnutrition in older adults with cancer. Researchers will follow 180 patients to see if nutrition status is linked to survival at 6 months and 1 year. The goal is to find better ways to identify and address malnutri…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Microdose cancer drug test could reveal best treatments without side effects
Knowledge-focused OngoingThis early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…
Phase: EARLY_PHASE1 • Sponsor: Presage Biosciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Cancer drug interaction study: will antibiotics change how cediranib works?
Knowledge-focused OngoingThis Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
PPE vs video: which makes patients feel more cared for?
Knowledge-focused OngoingThis study looks at whether cancer patients feel their doctors show more empathy during in-person visits with protective gear (PPE) or during video calls without it. About 107 adults from MD Anderson's emergency center will share their views after a conversation with their doctor…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Cancer imaging study pulled before starting
Knowledge-focused TerminatedThis study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…
Phase: EARLY_PHASE1 • Sponsor: University of Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Cannabis withdrawal in cancer patients: a hidden struggle during transplant?
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to find out how often cannabis withdrawal happens and how severe it is in patients with blood cancers who are hospitalized for a bone marrow transplant or CAR-T therapy. Researchers will track symptoms like mood changes and physical discomfort using a standard que…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
One workout could boost cancer fighters?
Knowledge-focused OngoingThis study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …
Phase: PHASE2 • Sponsor: Universität Duisburg-Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New app helps cancer patients get housing and food support
Knowledge-focused OngoingThis study tests a digital platform called ConnectedNest that helps cancer patients find and connect with social services like housing assistance, food aid, and financial help. About 400 adults with cancer in Minnesota will use the platform for 90 days. Researchers will measure i…
Phase: PHASE2 • Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Massive 75,000-Patient registry aims to unlock best uses of proton therapy
Knowledge-focused ENROLLING_BY_INVITATIONThis registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…
Sponsor: Loma Linda University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Patients claim cannabis stops tumor growth – scientists investigate
Knowledge-focused OngoingThis study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.
Sponsor: HealthPartners Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Why do cancer patients fear painkillers after surgery? new study investigates
Knowledge-focused OngoingThis study looks at why adults with cancer may fear taking opioid pain medication after surgery. Researchers will use questionnaires to measure barriers, fears, and medication adherence in 50 patients. The goal is to learn more about these concerns to improve pain management afte…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can a statin tame a cancer protein? early trial seeks answers
Knowledge-focused OngoingThis early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…
Phase: PHASE1 • Sponsor: Joaquina Baranda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can new outreach methods boost minority enrollment in cancer trials?
Knowledge-focused OngoingThis study looks at different ways to reach out to African American patients and their doctors to see if it helps more of them join early phase cancer treatment trials. About 134 people will take part. The goal is to find better methods to make cancer research more inclusive.
Phase: NA • Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Can tumor profiling help kids beat cancer? new study aims to find out
Knowledge-focused OngoingThis study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Smartwatches track cancer symptoms at home
Knowledge-focused ENROLLING_BY_INVITATIONThis study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Pregnancy DNA test may spot cancer in Moms-to-Be
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Simple senior health quiz may predict chemo dangers
Knowledge-focused OngoingThis study looks at whether a special health assessment for older adults with cancer can help doctors predict and reduce serious side effects from chemotherapy. About 600 patients with solid tumors will be evaluated before starting treatment. The goal is to improve care and quali…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Can tablets replace paper for senior cancer patients?
Knowledge-focused OngoingThis study looks at whether older adults with cancer can use computer surveys (like on a tablet or computer) to answer health questions. Researchers want to see if these digital tools are easy to use, reliable, and give the same results as paper surveys. About 100 people aged 65 …
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
What happens to your facebook when you die? new study explores
Knowledge-focused OngoingThis study from MD Anderson Cancer Center surveys 117 advanced cancer patients about whether they've discussed with family how to manage their social media accounts after death. The goal is to understand patient needs and identify sources of stress around digital legacy. Particip…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New study aims to improve cancer care for seniors
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether training and support can help cancer clinics give special check-ups (called geriatric assessments) to patients aged 65 and older who are starting a new cancer treatment. These check-ups help find and address health issues, support needs, and daily life…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New Full-Body PET scanner promises faster scans, less radiation
Knowledge-focused OngoingThis study compares a new total body PET scanner (Omni TB) with conventional PET in 25 adult cancer patients. The new scanner can image the whole body at once with higher sensitivity, potentially allowing shorter scan times and lower radiation doses. Researchers will assess wheth…
Phase: NA • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer pain app study pulled before it started
Knowledge-focused TerminatedThis study planned to create and test a cloud-based program for cancer patients to report their pain levels from home using a smartphone. The goal was to improve pain management and medication use. However, the study was withdrawn before any participants were enrolled.
Phase: NA • Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New study aims to better detect depression in older adults with cancer
Knowledge-focused OngoingThis study aims to create a more accurate way to measure depression in older adults who have or had cancer. Researchers will interview patients and test a new questionnaire designed specifically for this group. The goal is to improve how doctors identify and treat depression in o…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Tracking childhood cancer survivors for decades to improve their future health
Knowledge-focused OngoingThis long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New tool aims to predict chemo risks for seniors
Knowledge-focused OngoingThis study tests whether a geriatric assessment tool—looking at thinking, memory, daily activities, and emotional well-being—can predict serious side effects from chemotherapy in older adults with cancer. Over 1,000 patients completed questionnaires and cognitive tests before and…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New study aims to improve cancer pain management
Knowledge-focused OngoingThis study looks at how people with chronic cancer pain take their long-acting opioid medications. The goal is to learn from their experiences and develop a better way to manage cancer pain. About 150 adults who are prescribed long-acting opioids for cancer pain will participate.…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Skin sensor could alert doctors to rising pain in cancer and COPD patients
Knowledge-focused OngoingThis study tests whether a wearable skin sensor can tell the difference between mild, moderate, and severe pain in 37 adults with cancer or COPD. Participants wear the device for up to a week and report their pain levels. The goal is to create an algorithm that alerts caregivers …
Sponsor: Copenhagen University Hospital, Hvidovre • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Study probes Patients' minds, not their tumors
Knowledge-focused OngoingThis study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…
Sponsor: Tomas Bata Hospital, Czech Republic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Mice may hold key to better cancer drug choices
Knowledge-focused ENROLLING_BY_INVITATIONThis study takes a small piece of a patient's cancer and grows it in special mice. Doctors then test many different drugs on the mouse tumor to see which ones work best. The results are shared with the patient's oncologist, who decides if and how to use the information. The goal …
Sponsor: Certis Oncology Solutions, Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
CAR-T therapy patients monitored for years in new safety study
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…
Sponsor: AvenCell Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Lab test could match cancer patients to the right drugs
Knowledge-focused OngoingThis study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…
Sponsor: China Medical University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Racial gap in cancer treatment? new study investigates immunotherapy outcomes
Knowledge-focused OngoingThis study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…
Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New study aims to predict and prevent dangerous drug reactions
Knowledge-focused OngoingThis study looks at whether combining genetic tests, regular drug level checks, and careful medication reviews can help doctors prescribe the right drugs and avoid harmful side effects. It involves 450 adults with cancer and children with chronic inflammatory diseases. The goal i…
Sponsor: Direzione centrale salute, politiche sociali e disabilità • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New approach aims to boost cancer trial awareness and participation
Knowledge-focused OngoingThis study tests a communication method to help cancer patients and the general public learn about clinical trials and make informed decisions about joining. About 581 participants will receive information to increase their awareness and positive attitudes toward trials. The goal…
Phase: NA • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Real-Time proton beam tracking could sharpen cancer therapy
Knowledge-focused OngoingThis study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …
Sponsor: Shuanghu Yuan • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New MRI-Guided radiotherapy machine put to the test
Knowledge-focused OngoingThis study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Can a team of experts help older cancer patients bounce back after transplant?
Knowledge-focused OngoingThis study tests whether a program where older adults (65+) with blood cancer see a team of healthcare providers can help them stay fit and resilient after a stem cell transplant. The program includes health coaching, quality-of-life assessments, and questionnaires. The main goal…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
MRI-Guided radiation: a sharper weapon against cancer?
Knowledge-focused OngoingThis study is testing a new radiation technique that uses real-time MRI scans to target cancer more precisely. About 377 adult cancer patients will receive this treatment and have extra scans and quality-of-life surveys. The goal is to see if this approach improves tumor control …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Gut check: Antibiotics' hidden impact on transplant recovery
Knowledge-focused OngoingThis study looks at how different antibiotics change the friendly bacteria in the gut of people who have had a stem cell transplant and develop a fever with low white blood cells. The goal is to understand which antibiotics are gentler on these helpful bacteria, which may lead to…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Cancer's hidden toll: how it shapes who young survivors become
Knowledge-focused OngoingThis study looks at how surviving cancer as a teen or young adult affects a person's identity, friendships, and family life. Researchers will interview and hold group discussions with 300 survivors aged 15 to 25 who finished treatment at least 6 months ago. The goal is to learn w…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Can we track brain health in older cancer patients?
Knowledge-focused OngoingThis study looks at whether it's possible to track memory and thinking changes in adults aged 65 and older who are starting a new type of cancer treatment called immune checkpoint inhibitors. Thirty participants will take simple memory and concentration tests every six weeks for …
Sponsor: Our Lady's Hospice and Care Services • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Why do cancer patients fear painkillers? new study investigates
Knowledge-focused OngoingThis study looks at why some adults with advanced cancer are afraid to take opioids for pain, even when prescribed. Researchers will survey 50 patients to measure how fear, anxiety, and depression affect pain levels and medication use. The goal is to identify barriers so that pai…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Cancer Patients' pandemic struggles revealed in new study
Knowledge-focused OngoingThis study surveys over 1,200 cancer patients who previously took part in behavioral trials to learn how the COVID-19 pandemic impacted their quality of life, mental health, and daily routines. Participants fill out questionnaires about stress, sleep, diet, exercise, and social s…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
7,000 tumor samples analyzed to uncover Cancer's hidden support system
Knowledge-focused OngoingThis study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
New study examines immunotherapy outcomes in american indian cancer patients
Knowledge-focused OngoingThis study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Telehealth under the microscope: did virtual cancer care hold up during COVID?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how doctors and nurses in radiation oncology used telehealth instead of in-person visits during the COVID-19 pandemic. Researchers will survey 1,000 healthcare providers at Duke Cancer Center to understand their experiences and challenges. They will also track…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Can a short video help cancer patients get better palliative care?
Knowledge-focused OngoingThis study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…
Phase: NA • Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Italy launches massive genetic database to match cancer patients with better treatments
Knowledge-focused OngoingThis observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…
Sponsor: Federation of Italian Cooperative Oncology Groups • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Light therapy under the microscope: can it soothe mouth sores after transplant?
Knowledge-focused OngoingThis study looks at how photobiomodulation (a type of light therapy) affects mouth sores and other oral symptoms in patients receiving a stem cell transplant. Researchers will track pain, taste changes, and dry mouth in about 6 patients. The goal is to gather information to impro…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Expert panel boosts precision cancer care in new study
Knowledge-focused OngoingThis study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors get treatments that match their cancer's genetic makeup. About 1,284 patients will take part. The goal is to see if this team approach le…
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
New imaging agent could help spot tumors in future cancer trials
Knowledge-focused OngoingThis early-phase study tests a radioactive imaging drug called 124I-PUH71 in 63 people with non-Hodgkin's lymphoma, myeloma, or solid tumors. The goal is to see how the drug travels through the body and collects in tumors, and how long it stays in the blood. This is not a treatme…
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Withdrawn study sought to understand when lymphoma and cancer strike together
Knowledge-focused TerminatedThis study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New study seeks sharper MRI images for cancer treatment
Knowledge-focused TerminatedThis study aims to find the best MRI settings for the MR-linac, a machine that combines MRI and radiation therapy. Researchers will test different scan parameters in cancer patients and healthy volunteers to get clearer, more accurate images. The goal is to improve radiation ther…
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Can a smartphone app help young cancer survivors stay on track?
Knowledge-focused OngoingThis study tests a mobile app designed to help adolescent and young adult cancer survivors follow their personalized care plans. 25 survivors aged 15-29 who have finished cancer treatment will use the app to receive tailored text messages and educational content. The goal is to s…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Cancer Patients' COVID-19 secrets revealed in new study
Knowledge-focused OngoingThis study gathers information from cancer patients and their household members to better understand COVID-19 infections. Participants fill out online questionnaires about their health and lifestyle. The goal is to create a registry that helps researchers see how COVID-19 affects…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Can a smartphone app make radiation treatment less confusing?
Knowledge-focused OngoingThis pilot study tests a mobile app called oncpatient designed to help cancer patients navigate radiation therapy. The app provides easy-to-access information about treatment logistics and side effect management. Researchers will enroll 20 adults with cancer who are about to star…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Pandemic delays led to fewer cancer diagnoses, study of 438,000 cases shows
Knowledge-focused OngoingThis study looks at how the COVID-19 pandemic changed the number of new cancer cases in Bavaria, Germany. Researchers analyzed data from 438,000 adults diagnosed with cancer between 2018 and 2023 to see if certain regions or cancer types were more affected. The goal is to underst…
Sponsor: Bavarian Cancer Registry • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Young cancer survivors face hidden financial toll
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at financial problems (called 'financial toxicity') in young adults aged 18-39 who have finished cancer treatment. Researchers will survey 300 participants to measure money stress during and after therapy, and find out what factors make it worse. The goal is to l…
Sponsor: University Medical Center Goettingen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Timing is everything: new study tests if stem cell infusion time prevents transplant complications
Knowledge-focused OngoingThis study looks at whether the time when stem cells are given to blood cancer patients after a donor transplant affects their risk of developing acute graft-versus-host disease (aGVHD), a serious complication where donor cells attack the patient's body. About 198 patients aged 1…
Phase: PHASE3 • Sponsor: Anhui Provincial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Can laughter yoga and art therapy ease cancer distress?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how mind-body therapies—like mindfulness, laughter yoga, and art therapy—affect the quality of life and emotional distress of 150 cancer patients. Participants will fill out questionnaires before and after an 8-week program. The goal is to see if these therapi…
Sponsor: La Tour Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Hidden hepatitis b may wake up during cancer treatment – study watches closely
Knowledge-focused OngoingThis study follows 60 cancer patients who have a hidden form of hepatitis B (occult infection) and are receiving immunotherapy. The goal is to see how often the virus becomes active again, which could cause liver problems. Researchers will monitor blood tests and immune responses…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
New program aims to stop blood clots in cancer patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests a modified clinical program to help doctors better prevent blood clots (VTE) in cancer patients starting treatment. About 25 patients and their doctors will take part. The program includes education for doctors and a structured risk assessment to decide if blood-…
Phase: NA • Sponsor: University of Vermont • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Stem cells may unlock mystery of chemo-related heart damage
Knowledge-focused OngoingThis study uses stem cells made from patients' own cells to understand why some people develop severe heart or lung side effects from certain chemotherapy drugs. Researchers will compare cells from patients who had extreme toxicity to those who did not. The goal is to uncover the…
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New online tool aims to help older cancer patients get better treatment plans
Knowledge-focused OngoingThis study is testing an online questionnaire called CHAMP that older adults with cancer can fill out before their doctor's visit. The tool asks about daily function, memory, mood, and support to help doctors tailor cancer treatment. Researchers want to see if the tool is easy to…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Could your genes raise your lung cancer risk? new study investigates
Knowledge-focused OngoingThis study looks at whether certain inherited gene changes (EGFR mutations) increase the risk of lung cancer, especially in people who never smoked. Researchers collect saliva from cancer patients with a specific tumor mutation (T790M) to find these inherited changes. They also o…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New scanner aims to cut cancer scans in half
Knowledge-focused TerminatedThis study compares a new PET-CT scanner built into the RefleXion radiotherapy system with standard PET-CT scans in 20 adults with various cancers. The goal is to see if the new scanner can find the same cancer spots, so patients might need fewer scans before radiation therapy. T…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Gut bacteria could be key to better cancer immunotherapy
Knowledge-focused OngoingThis study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Shingles vaccine safety in pregnancy under review for immunocompromised women
Knowledge-focused OngoingThis study looks at whether the shingles vaccine (HZ/su) is safe for pregnant women aged 18-49 with weakened immune systems. Researchers will track about 2,800 women to see if the vaccine raises the risk of birth defects or other problems in their babies. The goal is to provide r…
Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Cancer Patients' vaccine response under microscope
Knowledge-focused OngoingThis study looks at how well cancer patients respond to common vaccines like flu, COVID-19, and shingles. Researchers will measure antibody levels before and after vaccination in 250 adults with cancer. The goal is to understand immune responses in this group, not to test a new t…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC